Skip to main content

Francesca Palandri, MD, PhD

Francesca Palandri, MD, PhD
Q&As
02/21/2024
Francesca Palandri, MD, PhD, evaluates the correlation between anemia and an increased risk of evolution into blast phase for patients with ruxolitinib-treated myelofibrosis.
Francesca Palandri, MD, PhD, evaluates the correlation between anemia and an increased risk of evolution into blast phase for patients with ruxolitinib-treated myelofibrosis.
Francesca Palandri, MD, PhD,...
02/21/2024
Oncology
Francesca Palandri, MD, PhD
Q&As
02/21/2024
Francesca Palandri, MD, PhD, discusses future possibilities and new breakthroughs in treatment strategies for patients with myelofibrosis, such as expanding treatment options for high-risk patients and more deeply considering the biology of...
Francesca Palandri, MD, PhD, discusses future possibilities and new breakthroughs in treatment strategies for patients with myelofibrosis, such as expanding treatment options for high-risk patients and more deeply considering the biology of...
Francesca Palandri, MD, PhD,...
02/21/2024
Oncology